Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” fourth quarter 2024 investor letter. A copy of the letter can be downloaded here. Small-cap stocks had mixed results in the fourth quarter, failing to match their previous quarter’s rebound. The Russell 2000® Growth Index rose 1.70%, outperforming the Russell 2000® Value Index, which fell 1.07%, ending in negative territory. Small caps had a strong year in 2024, with the Russell 2000 Growth Index rising 15.14%, nearly matching the previous year’s results and outperforming the Russell 2000 Value Index, which increased by 8.04% but saw a decline on an annual basis. In addition, please check the fund’s top five holdings to know its best picks in 2024.
In its fourth quarter 2024 investor letter, Carillon Eagle Small Cap Growth Fund emphasized stocks such as TransMedics Group, Inc. (NASDAQ:TMDX). TransMedics Group, Inc. (NASDAQ:TMDX) is a medical technology company. The one-month return of TransMedics Group, Inc. (NASDAQ:TMDX) was -2.10%, and its shares lost 4.05% of their value over the last 52 weeks. On March 24, 2025, TransMedics Group, Inc. (NASDAQ:TMDX) stock closed at $71.47 per share with a market capitalization of $2.406 billion.
Carillon Eagle Small Cap Growth Fund stated the following regarding TransMedics Group, Inc. (NASDAQ:TMDX) in its Q4 2024 investor letter:
“TransMedics Group, Inc. (NASDAQ:TMDX) focuses on the care, transport, and viability of donor organs using a fleet of aircraft and logistics center. Despite the high demand for viable donor organs, challenges remain in harvesting and preserving these organs efficiently. In the most recent quarter, Transmedics reported impressive revenue growth, but missed consensus expectations, attributing the shortfall to seasonality rather than to competition. Shortly before its investor day in December, Transmedics hired a new chief financial officer and lowered full-year guidance by several million dollars.”
A surgeon in a modern operating theatre performing a transplant surgery with medical technology.
TransMedics Group, Inc. (NASDAQ:TMDX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held TransMedics Group, Inc. (NASDAQ:TMDX) at the end of the fourth quarter compared to 32 in the third quarter. TransMedics Group, Inc. (NASDAQ:TMDX) reported $121.6 million in revenues in the fourth quarter, representing 49.8% year-over-year growth and 11.8% sequential growth from Q3 2024. While we acknowledge the potential of TransMedics Group, Inc. (NASDAQ:TMDX) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
In another article, we discussed TransMedics Group, Inc. (NASDAQ:TMDX) and shared the list of Wasatch Small Cap Growth Strategy’s views on the company. In addition, please check out our hedge fund investor letters Q4 2024 page for more investor letters from hedge funds and other leading investors.
READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks.
Disclosure: None. This article is originally published at Insider Monkey.